Clinical Development

Howard Burt

PBPK Modeling and Simulation expert

Howard Burt obtained a PhD in Pharmacokinetics in 2008 from the Centre of Applied Pharmacokinetic Research (CAPKR) at the University of Manchester, UK. Following this he worked as a post-doctoral scientist in both academia (CAPKR) and industry (Merck Serono). Since 2011 he has worked within the Translational Science in DMPK group at Simcyp. This has involved the development of the mechanistic models within the Simcyp Simulator, as well as consultancy projects. 

Wilma Bagchus

Global Early Development Lead (Clinical Pharmacology)

Wilma Bagchus currently works at the US affiliate of Merck KGaA, Darmstadt, Germany and was educated as a medical biologist, holding a PhD in medicine and registered as an Immunologist. She has 24 years of experience in drug development in the pharmaceutical industry starting in Research.  She held the last 15 years various positions as a Clinical Pharmacologist doing First in Men and Clinical Pharmacology trials for different development projects in various therapeutic areas. 

Deon Bezuidenhout

Site relationship and operations lead

Deon Bezuidenhout has worked at the South African Affiliate of Merck KGaA,Darmstadt, Germany since 2013 and currently fulfills the positions of Site Relationship & Operations lead and Clinical Research Manager. Deon brings 10 years of experience in different positions in clinical trial management across a wide range of therapeutic areas, including Malaria and HIV/Aids. He has a Diploma Leading to Registration as a professional nurse.

Paul Passier

Director Clinical Pharmacology

Paul Passier has a PhD in Neuroendocrinology and is registered as a clinical pharmacologist. He joined the pharmaceutical industry in 1996 and has worked in several positions at Solvay, Organon and Schering-Plough. Since 2008 he works at the clinical pharmacology and exploratory development department of Astellas, where he now focuses on the therapeutic area of urology. He has also been heavily involved in the pediatric development program of one of the urology products of Astellas.

Marc Urich

Clinical Trial Management

Marc Urich is heading the Pharmaceutical Medicines Unit (Dept of Medicines Research) at Swiss TPH in Basel, Switzerland. Prior to his position at Swiss TPH he worked for more than ten years in the pharmaceutical industry. During that time he gained extensive experience in the management of clinical phase IIIb/IV trials and Investigator-initiated studies. Marc Urich has a PhD in biochemistry from the Friedrich Miescher Institute in Basel, Switzerland.

Eric Huber

Clinical Trial Management

Eric Huber is a Project Leader in the Pharmaceutical Medicines Unit at the Swiss Tropical and Public Health Institute (Swiss TPH) in Basel, Switzerland. He leads the planning, organization, management & monitoring of trials, with a focus on neglected diseases. Through this work, he has gained extensive experience in the management of clinical phase I to IV vaccine and drug trials. In addition, he organizes and contributes to capacity building projects.

Aliona Tappert is a physician specialized in General Medicine and Dermato-venerology. She had worked in different hospitals as medical practitioner before switching to Pharma. She has more than 10 years of cross-functional R&D experience in the pharmaceutical industry including Literature Review Expert/ Medical Evaluator, Clinical Trials Group Manager, Business Development- and Project Manager/ Clinical Trials Center. Aliona joined Merck KGaA Darmstadt, Germany, in October 2011 where she has been working since then as Global Drug Safety Product Leader, being accountable for all medical safety aspects of assigned medicinal products.

Brooke Ro

Global Biostatistics

Brooke Hayward Ro has been at EMD Serono, the US affiliate of Merck KGaA, Darmstadt, Germany, supporting late phase and observational studies across various therapeutic areas since 2009. Prior to EMD Serono, she was the lead biostatistician for 3 simultaneous global regulatory submissions – one of these included a pediatric indication and was the first product approved by the FDA based on a Bayesian primary endpoint. She has a master’s degree in biostatistics from Harvard University and an MBA from Yale University.